The Manufacturers Life Insurance Company cut its stake in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 20.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 86,366 shares of the company’s stock after selling 22,079 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.06% of Vaxcyte worth $5,019,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. T. Rowe Price Investment Management Inc. increased its position in shares of Vaxcyte by 35.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock valued at $521,213,000 after buying an additional 2,981,038 shares during the period. Caligan Partners LP purchased a new stake in Vaxcyte in the fourth quarter worth about $78,660,000. Adage Capital Partners GP L.L.C. boosted its position in Vaxcyte by 418.0% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,725,000 shares of the company’s stock valued at $79,592,000 after acquiring an additional 1,392,000 shares in the last quarter. Polar Capital Holdings Plc grew its holdings in shares of Vaxcyte by 302.6% during the 4th quarter. Polar Capital Holdings Plc now owns 1,672,783 shares of the company’s stock worth $77,182,000 after acquiring an additional 1,257,253 shares during the period. Finally, Norges Bank purchased a new position in shares of Vaxcyte during the 4th quarter worth approximately $56,703,000. 96.78% of the stock is owned by hedge funds and other institutional investors.
Vaxcyte Stock Performance
NASDAQ:PCVX opened at $58.89 on Friday. The firm has a market cap of $8.50 billion, a P/E ratio of -7.72 and a beta of 1.23. Vaxcyte, Inc. has a fifty-two week low of $29.08 and a fifty-two week high of $65.00. The firm has a 50-day simple moving average of $53.72 and a two-hundred day simple moving average of $55.19.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on the company. Zacks Research cut Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $86.00.
Read Our Latest Report on Vaxcyte
More Vaxcyte News
Here are the key news stories impacting Vaxcyte this week:
- Positive Sentiment: Quarterly loss beat expectations: Vaxcyte reported second-quarter 2026 EPS of negative $1.97, better than analysts’ consensus estimate of negative $2.06. However, the loss was wider than the negative $1.22 reported in the year-earlier quarter. Vaxcyte quarterly earnings release
- Positive Sentiment: Multiple clinical catalysts are ahead: Topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial are expected in the fourth quarter of 2026. Results from OPUS-2 and OPUS-3 are expected in the first half of 2027, while infant VAX-31 data are expected by the end of the first half of 2027. Vaxcyte second-quarter business update
- Positive Sentiment: Strong liquidity supports development: Vaxcyte held approximately $2.5 billion in cash, cash equivalents and investments at June 30, 2026. The balance sheet reduces near-term financing concerns as the company advances its late-stage vaccine programs and VAX-A1.
- Neutral Sentiment: Institutional ownership remains high: Several funds, including Royal Bank of Canada, UBS Asset Management and Cetera Investment Advisers, increased their positions recently. Institutional investors and hedge funds collectively own approximately 96.8% of outstanding shares.
- Negative Sentiment: Executives reported stock sales: The CFO, COO and another insider sold a combined 29,250 shares worth roughly $1.6 million. The transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may still weigh modestly on sentiment. Vaxcyte insider selling report
- Negative Sentiment: Losses are expected to continue: Analysts forecast a full-year 2026 loss of approximately $7.91 per share, underscoring Vaxcyte’s dependence on successful clinical execution and future commercialization.
Insider Activity
In related news, CEO Grant Pickering sold 22,461 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $52.50, for a total value of $1,179,202.50. Following the transaction, the chief executive officer directly owned 474,703 shares of the company’s stock, valued at approximately $24,921,907.50. This represents a 4.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $49.52, for a total value of $111,420.00. Following the sale, the chief operating officer owned 158,494 shares in the company, valued at approximately $7,848,622.88. This represents a 1.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 120,646 shares of company stock valued at $6,570,810 in the last quarter. Insiders own 3.30% of the company’s stock.
Vaxcyte Profile
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
Featured Articles
- Five stocks we like better than Vaxcyte
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.
